Cellphire, Inc.
- | Biotech or pharma, therapeutic R&D
No-one Should Die from Controllable Hemorrhage! Addressing US and Global unmet hemorrhage control needs, Cellphire Therapeutics is the global leader in proprietary, novel platelet derived therapeutics. We are revolutionizing bleeding treatment with platelet derived therapeutics. While platelet derived therapeutics have a broad range of potential uses, Cellphire currently focuses on internal hemorrhage. The company’s two clinical stage products are well advanced: (1) late stage CLPH-511, addressing a >$700 mm US unmet need, is expected for commercial launch in 2027; and (2) FPH, a first-in-class, first-line biologic in Phase 2 addresses the >$3.5 BN US market for acute bleeding, including anti-platelet & anti-coagulation reversal, post-partum hemorrhage, and Intracranial Hemorrhage-Traumatic Brain Injury (ICH/TBI). Led by a team with a strong track record developing and commercializing assets, Cellphire has received non-dilutive funding in excess of $155 mm.
Address
RockvilleMD
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}